{ "schema_version": 1, "kind": "condition", "id": "septic-arthritis-referral", "name": "Septic Arthritis (Emergency Referral)", "category": "infectious", "sources": "BSR guideline scope: Management of septic arthritis in adults with a hot swollen joint (Rheumatol Adv Pract 2025;9(3):rkaf058) · BSR/BHPR/BOA/RCGP/BSAC guideline for management of the hot swollen joint in adults (Coakley et al, Rheumatology 2006;45:1039-41) · Knee Arthrocentesis - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470229/ · Septic Arthritis: Diagnosis and Treatment (Am Fam Physician 2021;104(6):589-597) · Egyptian National Drug Formulary - Antimicrobial 2023 (vancomycin monograph, p333) · Egyptian National Drug Formulary - Antimicrobial 2023 (ceftriaxone monograph, p255)", "review_status": "reviewed", "verified_against": "Egyptian National Drug Formulary - Antimicrobial 2023 (vancomycin monograph, p333) · Egyptian National Drug Formulary - Antimicrobial 2023 (ceftriaxone monograph, p255)", "verified_date": "2026-08", "treatments": [ { "id": 1672, "generic": "Vancomycin", "line": 1, "is_adjunct": false, "form": "injection", "strength_mg": 500.0, "adult_dose": "Intravenous. Where a loading dose is used the formulary gives 25 to 30 mg/kg, then 15 to 20 mg/kg every 8 to 12 hours at normal renal function, adjusted afterwards on measured blood levels.", "adult_duration": "About 2 weeks intravenously, then 1 to 2 weeks orally - 3 to 4 weeks in total, and 4 to 6 weeks where Pseudomonas is grown", "dose_source": "Egyptian National Drug Formulary - Antimicrobial 2023 (vancomycin monograph, p333)", "rationale": "The card's article states that empirical antibiotic coverage includes antistaphylococcal coverage - nafcillin, oxacillin or vancomycin - for all age and risk categories, and that empirical treatment of non-gonococcal septic arthritis usually involves intravenous vancomycin against gram-positive organisms, especially where MRSA is suspected on local data. It states no amount. The amounts here are the Egyptian formulary's, and the formulary states them only inside its renal-adjustment table: the first row of that table is normal renal function.", "cautions": [ "NAFCILLIN AND OXACILLIN ARE NOT REGISTERED IN EGYPT. The article names all three; only vancomycin is on the Egyptian register, which is why it is the row.", "THE DOSE IS SET BY BLOOD LEVELS, NOT BY THE NUMBER ABOVE. The formulary asks for initial dosing on actual body weight and for every subsequent dose to be adjusted on therapeutic monitoring, and for levels to be monitored in any degree of renal impairment. The figure printed is a starting point for a patient with normal kidneys.", "THE KIDNEYS DECIDE THE INTERVAL, AND MOSTLY NOT THE DOSE. In the formulary's adult table the maintenance dose is 15 to 20 mg/kg both above a creatinine clearance of 90 and in the 50 to 90 band; what changes between them is the interval, 8 to 12 hours becoming 12 hours, and the loading dose, 25 to 30 mg/kg becoming 20 to 25 mg/kg. Only below a clearance of 50 does the maintenance dose itself fall, to 10 to 15 mg/kg every 24 hours. The paediatric table is separate and is keyed on GFR: 10 mg/kg per dose every 12 hours at a GFR of 30 to 50, every 18 to 24 hours at 10 to 29, and at under 10 a single 10 mg/kg dose redosed on measured levels.", "DRAINING THE JOINT IS HALF THE TREATMENT. The article's regimen is antimicrobial therapy AND joint fluid drainage by arthrotomy, arthroscopy or daily needle aspiration, with the orthopaedic surgeon deciding which. Antibiotics alone are not the treatment.", "ASPIRATE BEFORE THE FIRST DOSE WHERE THAT IS POSSIBLE. The article asks for empirical intravenous therapy to start promptly after joint aspiration is complete and cultures are taken - starting antibiotics first can make the culture unreadable.", "THIS IS A HOSPITAL INFUSION, NOT A CLINIC DRUG. The regimen is printed so the GP knows what the patient is being sent for and can recognise it, not so it is started in the surgery. Referral comes first.", "Do not give in hypersensitivity to vancomycin or any component of the formulation." ], "peds_mgkg_low": 10.0, "peds_mgkg_high": 15.0, "peds_max_mg": null, "peds_basis": "dose", "peds_unit": "mg", "peds_note": "The formulary prints no ordinary paediatric dose for vancomycin. It appears only as the stated baseline of the renal-adjustment table: those adjustments are based on intravenous doses of 10 mg/kg every 6 hours or 15 mg/kg every 8 hours. Both are per dose, not per day, and each figure is locked to its own interval: 10 mg/kg goes six-hourly and 15 mg/kg goes eight-hourly, which come to 40 and 45 mg/kg a day. They are not a range to pick from freely: pairing the higher amount with the shorter interval gives a daily total the formulary states nowhere. No paediatric ceiling is printed because the formulary states none - the dose is set by measured blood levels, not by a cap.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": [ { "weight_kg": 10, "low_mg": 100, "high_mg": 150, "capped": false }, { "weight_kg": 20, "low_mg": 200, "high_mg": 300, "capped": false }, { "weight_kg": 30, "low_mg": 300, "high_mg": 450, "capped": false }, { "weight_kg": 40, "low_mg": 400, "high_mg": 600, "capped": false } ], "brands": [ { "trade_name": "KEMPOVANCOM 500 MG VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "KAHIRA > MODERN OFFICE FOR IMPORT", "price_egp": 18.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "VANCOZIN 500 MG VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EIMC > KOREA UNITED PHARMA", "price_egp": 38.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "VANCOMIX 500MG I.V. VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA TEC", "price_egp": 79.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "VANCOGUT 500 MG PD. FOR I.V. INF. VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ARABCOMED", "price_egp": 95.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "VANCOLON 500MG I.V. VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "JULPHAR", "price_egp": 95.5, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "EDICIN 500 MG PD FOR I.V. INF. VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "GLOBAL PHARMACEUTICAL INDUSTRIES", "price_egp": 118.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "VANCOBACT 500 MG VIAL FOR I.V. INF.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ARABCOMED > EGYPHARMA", "price_egp": 118.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "VANCOMYCINE VIATRIS 500 MG VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "VIANAX - GREECE > ONE PHARMA MEDICS", "price_egp": 142.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "septic-arthritis-referral" }, { "id": 1673, "generic": "Ceftriaxone", "line": 1, "is_adjunct": false, "form": "injection", "strength_mg": 1000.0, "adult_dose": "1 to 2 g intravenously or intramuscularly once daily, or the same total divided into two doses. Maximum 4 g daily.", "adult_duration": "Added to the antistaphylococcal cover for the same course; in gonococcal arthritis it is continued for 24 to 48 hours after improvement, then oral treatment for the rest", "dose_source": "Egyptian National Drug Formulary - Antimicrobial 2023 (ceftriaxone monograph, p255)", "rationale": "The card's article states that where the patient is immunocompromised, injects drugs, or the Gram stain is negative, a third-generation cephalosporin such as ceftriaxone, ceftazidime or cefotaxime should be added for gram-negative cover, and that gonococcal arthritis responds well to intravenous ceftriaxone. It states no amount. The amount is the Egyptian formulary's, whose ceftriaxone monograph names septic arthritis in its own indication list.", "cautions": [ "THIS IS AN ADDITION FOR SELECTED PATIENTS, NOT THE ROUTINE SECOND DRUG. The article adds the cephalosporin where the patient is immunocompromised, injects drugs, or the Gram stain is negative, and for suspected Salmonella or gonococcal infection. Everyone gets the antistaphylococcal cover; not everyone gets this.", "NOT IN A NEONATE ALONGSIDE INTRAVENOUS CALCIUM. The formulary contraindicates ceftriaxone with intravenous calcium-containing products in a neonate of 28 days or under, and in a jaundiced neonate - especially a premature one - because it displaces bilirubin from albumin. Cefotaxime is the third-generation cephalosporin to use there.", "THE CULTURE DECIDES WHAT FOLLOWS. The article asks for blood and synovial fluid cultures and sensitivities to direct the prolonged course; this empirical choice lasts until they come back.", "IF NOTHING IMPROVES IN 5 TO 6 DAYS, THE ANSWER IS NOT MORE ANTIBIOTIC. The article asks for the joint to be re-aspirated and for Lyme disease and other causes to be ruled out.", "Do not give in hypersensitivity to ceftriaxone, any component, or another cephalosporin." ], "peds_mgkg_low": 100.0, "peds_mgkg_high": 100.0, "peds_max_mg": 2000.0, "peds_basis": "day", "peds_unit": "mg", "peds_note": "The formulary gives two paediatric figures by severity, and the one printed is the severe-infection figure, because a joint that needs draining is not a mild infection: 100 mg/kg/day divided every 12 to 24 hours. Its mild-to-moderate figure is lower - 50 to 75 mg/kg once daily, maximum 1,000 mg/day. The formulary states three ceilings and they do not agree. The severe-infection dose line itself carries a maximum of 4,000 mg a day. Its Prescribing Limits section separately caps a child at 2 g daily for most infections and at 4 g daily for endocarditis or meningitis. The 2 g figure is the one applied above, because septic arthritis is neither endocarditis nor meningitis - which means the calculator stops rising at 20 kg, and a 30 kg child is shown 2,000 mg where 100 mg/kg would be 3,000 mg. The formulary supports the higher figure on its own dose line; the lower one is used here, and both are written out so the choice is visible rather than silent. A premature or term neonate is dosed separately at 50 mg/kg every 24 hours.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": [ { "weight_kg": 10, "low_mg": 1000, "high_mg": 1000, "capped": false }, { "weight_kg": 20, "low_mg": 2000, "high_mg": 2000, "capped": false }, { "weight_kg": 30, "low_mg": 2000, "high_mg": 2000, "capped": true }, { "weight_kg": 40, "low_mg": 2000, "high_mg": 2000, "capped": true } ], "brands": [ { "trade_name": "ZOXIDEL 1 GM PD. FOR I.M. INJ.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RAMEDA > DELTA PHARMA", "price_egp": 22.0, "pack_count": null, "unit_price": null, "strength_mg": 1000.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CEFTRIAXONE SODIUM 1 GM I.M.VIAL (KAHIRA)", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "KAHIRA", "price_egp": 29.0, "pack_count": null, "unit_price": null, "strength_mg": 1000.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ZOXIDEL 1 GM PD. FOR I.V. INJ.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RAMEDA > DELTA PHARMA", "price_egp": 29.0, "pack_count": null, "unit_price": null, "strength_mg": 1000.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "WINTRIAXONE 1 GM PD. FOR I.V INJ.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 48.0, "pack_count": null, "unit_price": null, "strength_mg": 1000.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "VOTRIAXONE 1 GM I.M VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "CHEMIPHARM", "price_egp": 56.0, "pack_count": null, "unit_price": null, "strength_mg": 1000.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "OFRAMAX 1 GM I.M. VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RAMEDA > SUN PHARMA EGYPT LIMITED", "price_egp": 71.0, "pack_count": null, "unit_price": null, "strength_mg": 1000.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "TRIAXONE 1 GM I.M. VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "TABUK PHARMACEUTICAL MANUFACTURING COMPANY > TABUK PHARMA", "price_egp": 106.0, "pack_count": null, "unit_price": null, "strength_mg": 1000.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "TRIAXONE 1 GM I.V VIAL", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "TABUK PHARMACEUTICAL MANUFACTURING COMPANY > TABUK PHARMA", "price_egp": 106.0, "pack_count": null, "unit_price": null, "strength_mg": 1000.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "septic-arthritis-referral" }, { "id": 1674, "generic": "Referral & safety-netting (no drug therapy)", "line": 1, "is_adjunct": false, "form": null, "strength_mg": null, "adult_dose": "Same-day referral to a hospital specialist who can aspirate the joint. Do NOT start an antibiotic in the clinic first.", "adult_duration": "Immediate same-day referral", "dose_source": "No dose - emergency referral pathway, no medicine given in primary care", "rationale": "BSR 2006 grade B: the synovial fluid must be aspirated, Gram-stained and cultured prior to starting antibiotics. An antibiotic given before aspiration can sterilise the sample, so the organism is never identified and the six-week course cannot be targeted. BSR 2006 grade C: GPs should refer to a specialist within the hospital who has the expertise to aspirate the joint. Untreated or delayed, the joint is destroyed; the 2006 guideline reports a case fatality of 11%.", "cautions": [ "DO NOT give an antibiotic before the joint is aspirated - it sterilises the sample and the organism is then never identified (BSR 2006, grade B).", "TIME-CRITICAL: treat any acutely hot, swollen, painful joint as septic until aspiration proves otherwise, even when gout or a flare of known arthritis looks more likely.", "Normal CRP, ESR or white cell count DO NOT exclude septic arthritis, and neither does the absence of fever (BSR 2025 scope).", "A prosthetic or otherwise non-native joint must go to an orthopaedic surgeon, and must not be aspirated outside a sterile environment (BSR 2006 grade C; BSR 2025 scope).", "Risk is higher with previous joint surgery, prosthetic joint, recent joint injection, rheumatoid arthritis, skin infection or ulcer, diabetes, and immunosuppression.", "If the patient is also systemically unwell with signs of sepsis, the sepsis pathway takes priority - see Suspected Sepsis - and antibiotics should not be withheld waiting for aspiration.", "In a sexually active adult consider gonococcal septic arthritis, which can present with migratory joint pain, tenosynovitis and a rash (Am Fam Physician 2021)." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "The BSR guideline covers adults only; a separate BSR guideline for the hot, swollen or stiff joint in children and young people is still in development. Refer any child with a hot, swollen, painful joint, or a limp with fever, the same day. Do not start an antibiotic first.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [], "condition_id": "septic-arthritis-referral" } ] }